Session » (L07–L17) Late-Breaking Abstract Poster
- 1:00PM-3:00PM
-
Abstract Number: L14
Bimekizumab Maintains Improvements in Efficacy Endpoints and Has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies
- 1:00PM-3:00PM
-
Abstract Number: L08
Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders
- 1:00PM-3:00PM
-
Abstract Number: L15
Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study
- 1:00PM-3:00PM
-
Abstract Number: L10
Efgartigimod Prevents Necrosis and Allows for Muscle Fiber Regeneration in a Humanized Mouse Model of Immune-mediated Necrotizing Myopathy (IMNM)
- 1:00PM-3:00PM
-
Abstract Number: L17
Evaluating the Safety and Factors Associated with Treatment Cessation in Takayasu Arteritis
- 1:00PM-3:00PM
-
Abstract Number: L13
Fetal Cardiac Targets Identify the Autoantibodies Associated with Congenital Heart Block
- 1:00PM-3:00PM
-
Abstract Number: L12
First Line Treatment Using Recombinant IL-1Receptor Antagonist in New Onset Systemic Juvenile Idiopathic Arthritis Is an Effective Treatment Strategy, Irrespective of HLA DRB1 Background
- 1:00PM-3:00PM
-
Abstract Number: L09
Impact on Access to Methotrexate in the Post-Roe Era
- 1:00PM-3:00PM
-
Abstract Number: L16
Innovative Anti-pneumococcal Vaccine Strategies versus Standard Vaccination Regimen in Patients with ANCA-associated Vasculitides Receiving Rituximab Therapy: A Multicenter Randomized Controlled Trial (PNEUMOVAS)
- 1:00PM-3:00PM
-
Abstract Number: L11
Romosozumab versus Denosumab in High-risk Patients with Glucocorticoid-induced Osteoporosis: A Pilot Randomized Controlled Trial